Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase Ib/III Study to Evaluate the Safety and Efficacy of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT05314010 is registered in ClinicalTrials.gov with Beijing Mabworks Biotech Co., Ltd. as lead sponsor.

NCT NCT05314010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05314010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase Ib/III Study to Evaluate the Safety and Efficacy of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Lead sponsor
Beijing Mabworks Biotech Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 18, 2022
Completion date
March 31, 2027
Enrollment
102 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica spectrum disorder